These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 10683053

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
    Palmer CS, Zhan C, Elixhauser A, Halpern MT, Rance L, Feagan BG, Marrie TJ.
    Clin Ther; 2000 Feb; 22(2):250-64. PubMed ID: 10743984
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
    Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, Fernández-Agüera A, Verdaguer R, Martínez J, Manresa F, Gudiol F.
    Ann Intern Med; 2005 Feb 01; 142(3):165-72. PubMed ID: 15684204
    [Abstract] [Full Text] [Related]

  • 6. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.
    Curr Med Res Opin; 2009 Apr 01; 25(4):859-68. PubMed ID: 19231913
    [Abstract] [Full Text] [Related]

  • 7. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
    Marrie TJ.
    Chemotherapy; 2004 Apr 01; 50 Suppl 1():11-5. PubMed ID: 15319549
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H, Song X, Crespi S, Navaratnam P.
    Value Health; 2009 Apr 01; 12(8):1135-43. PubMed ID: 19695010
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment].
    Ruiz A, Falguera M, Sacristán O, Vallverdú M, Cabré X, Pérez J, Ferrer G.
    Med Clin (Barc); 2002 Nov 16; 119(17):641-3. PubMed ID: 12453372
    [Abstract] [Full Text] [Related]

  • 14. [Update on the role of levofloxacin in the management of acute community-acquired pneumonia].
    Bru JP.
    Presse Med; 2002 Jun 15; 31(21 Pt 2):S19-22. PubMed ID: 12148386
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.